A double blind clinical study of adenine arabinoside therapy of viral keratoconjunctivitis.
D000225:Adenine / Q000009:adverse effects / Q000627:therapeutic use; D000257:Adenoviridae Infections / Q000188:drug therapy; D000998:Antiviral Agents; D001089:Arabinose / Q000009:adverse effects / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004342:Drug Hypersensitivity; D005069:Evaluation Studies as Topic; D006801:Humans; D007065:Idoxuridine / Q000009:adverse effects / Q000627:therapeutic use; D007635:Keratitis, Dendritic / Q000188:drug therapy; D007637:Keratoconjunctivitis / Q000188:drug therapy*; D009705:Nucleosides / Q000009:adverse effects / Q000627:therapeutic use*; D013997:Time Factors; D014605:Uveitis / Q000188:drug therapy; D014615:Vaccinia / Q000188:drug therapy; D014777:Virus Diseases / Q000188:drug therapy*
D000998:Antiviral Agents; D009705:Nucleosides; D001089:Arabinose; D000225:Adenine; D007065:Idoxuridine